[go: up one dir, main page]

WO2002020571A3 - Attenuated hiv strains and use thereof - Google Patents

Attenuated hiv strains and use thereof Download PDF

Info

Publication number
WO2002020571A3
WO2002020571A3 PCT/EP2001/010244 EP0110244W WO0220571A3 WO 2002020571 A3 WO2002020571 A3 WO 2002020571A3 EP 0110244 W EP0110244 W EP 0110244W WO 0220571 A3 WO0220571 A3 WO 0220571A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
hiv strains
immunodeficiency virus
attenuated hiv
human immunodeficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/010244
Other languages
French (fr)
Other versions
WO2002020571A2 (en
Inventor
Jaap Goudsmit
Marion Cornelissen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux BV
Original Assignee
Biomerieux BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux BV filed Critical Biomerieux BV
Priority to EP01982248A priority Critical patent/EP1315799A2/en
Priority to AU2002213882A priority patent/AU2002213882A1/en
Publication of WO2002020571A2 publication Critical patent/WO2002020571A2/en
Anticipated expiration legal-status Critical
Publication of WO2002020571A3 publication Critical patent/WO2002020571A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides an isolated human immunodeficiency virus, comprising at least one non revertant mutation capable of delaying or diminishing the pathological behavior of said immunodeficiency virus when compared to a human immunodeficiency virus not having at least one such a mutation. A virus of the invention can be used for the preparation of a vaccine for Aids. Said virus can also be used for diagnostic assays in HIV-infected patients.
PCT/EP2001/010244 2000-09-08 2001-09-05 Attenuated hiv strains and use thereof Ceased WO2002020571A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01982248A EP1315799A2 (en) 2000-09-08 2001-09-05 Attenuated hiv strains and use thereof
AU2002213882A AU2002213882A1 (en) 2000-09-08 2001-09-05 Attenuated hiv strains and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00203116.9 2000-09-08
EP00203116 2000-09-08

Publications (2)

Publication Number Publication Date
WO2002020571A2 WO2002020571A2 (en) 2002-03-14
WO2002020571A3 true WO2002020571A3 (en) 2003-03-13

Family

ID=8171998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010244 Ceased WO2002020571A2 (en) 2000-09-08 2001-09-05 Attenuated hiv strains and use thereof

Country Status (3)

Country Link
EP (1) EP1315799A2 (en)
AU (1) AU2002213882A1 (en)
WO (1) WO2002020571A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270464B1 (en) 1998-06-22 2001-08-07 Artemis Medical, Inc. Biopsy localization method and device
AU2001232485A1 (en) 2000-01-13 2001-07-24 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US8206913B1 (en) 2003-03-07 2012-06-26 Rubicon Genomics, Inc. Amplification and analysis of whole genome and whole transcriptome libraries generated by a DNA polymerization process
US7718403B2 (en) 2003-03-07 2010-05-18 Rubicon Genomics, Inc. Amplification and analysis of whole genome and whole transcriptome libraries generated by a DNA polymerization process
US8440404B2 (en) 2004-03-08 2013-05-14 Rubicon Genomics Methods and compositions for generating and amplifying DNA libraries for sensitive detection and analysis of DNA methylation
EP1924705A1 (en) 2005-08-02 2008-05-28 Rubicon Genomics, Inc. Isolation of cpg islands by thermal segregation and enzymatic selection-amplification method
ATE510930T1 (en) 2005-08-02 2011-06-15 Rubicon Genomics Inc COMPOSITIONS AND METHODS FOR EDITING AND AMPLIFICATION OF DNA USING MULTIPLE ENZYMES IN A SINGLE REACTION
CA2631881C (en) * 2005-12-07 2015-03-24 Tibotec Pharmaceuticals Ltd. Methods, plasmid vectors and primers for assessing hiv viral fitness
TR201809355T4 (en) * 2011-08-24 2018-07-23 Grifols Therapeutics Llc COMPOSITIONS AND METHODS FOR NUCLEIC ACID HYBRIDIZATION
WO2016172465A1 (en) * 2015-04-24 2016-10-27 The Johns Hopkins University Compositions and methods related to characterizing proviral reservoirs
US20230122226A1 (en) * 2020-03-05 2023-04-20 Board Of Regents Of The University Of Nebraska Crispr/cas9 system for multistrain hiv-1 treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017825A1 (en) * 1993-02-05 1994-08-18 The Regents Of The University Of California Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017825A1 (en) * 1993-02-05 1994-08-18 The Regents Of The University Of California Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AAVV: "Human Retroviruses and AIDS Compendium, Part III", 1999, LOS ALAMOS NATIONAL LABORATORY, USA, XP002209704 *
ALEXANDER L. ET AL.: "Unusual polymorphism in Human Immunodeficiency Virus Type 1 associated with nonprogressive infection.", J. VIROL., vol. 74, no. 9, May 2000 (2000-05-01), pages 4361 - 4376, XP002159810 *
CASELLA C.R. ET AL.: "Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication", VIROLOGY, vol. 228, 1997, pages 294 - 306, XP002159813 *
DATABASE NCBI [online] 23 November 1999 (1999-11-23), "HIV1 gag protein variant", XP002209705, retrieved from NCBI Database accession no. AAD41167 *
DATABASE NCBI [online] IWATANI: "HIV1 Gag variant", XP002209760, retrieved from NCBI Database accession no. BAA12996 *
FURUTA R.A. ET AL.: "HIV-1 capsid mutants inhibit the replication of wild-type virus at both early and late infection phases", FEBS LETTERS, vol. 415, 1997, pages 231 - 234, XP002159812 *
WANG C.T. ET AL.: "Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release.", J. VIROLOGY, vol. 72, no. 10, October 1998 (1998-10-01), pages 7950 - 7959, XP002159811 *

Also Published As

Publication number Publication date
EP1315799A2 (en) 2003-06-04
WO2002020571A2 (en) 2002-03-14
AU2002213882A1 (en) 2002-03-22

Similar Documents

Publication Publication Date Title
WO2002064615A3 (en) Monoclonal antibodies to human immunodeficiency virus and uses thereof
EP0887427A3 (en) Amplification and detection of hiv-1 and/or hiv-2
DE69737736D1 (en) INDUCTION OF REV AND TAT-SPECIFIC CYTOTOXIC T CELLS FOR THE PREVENTION AND TREATMENT OF INFECTION BY HUMAN IMMUNODICITY VIRUS (HIV)
TR200001553T2 (en) HIV-1 Tat or its derivatives.
WO2001054719A3 (en) Vaccine for the prophylactic or therapeutic immunization against hiv
EP1246644A4 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
DE60023300D1 (en) USE OF CPG AS ADJUVANS FOR HIV PULP
EP2280073A3 (en) Vaccine for prevention and treatment of HIV-infection
WO2002020571A3 (en) Attenuated hiv strains and use thereof
EP1375652A3 (en) Oral compositions for HIV-Infected Subjects
EP1026263A3 (en) Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2 and methods of use thereof
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
EP0402132A3 (en) Method for the detection of human papilloma-virus
MY134041A (en) Novel composition
WO2000061067A3 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
MY126450A (en) Crystalline efavirenz
AU5327298A (en) Non-M, non-O HIV-1 strains, fragments and uses
WO2002035981A3 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO2001060838A3 (en) Aids ancestral viruses and vaccines
WO2004070002A3 (en) Cell lines and host nucleic acid sequences related to infectious disease
ITVR940096A0 (en) PROCEDURE AND EQUIPMENT FOR THE SPECIFIC IMMUNADORPTION OF HIV VIRUS, GP120 ANTIGEN AND CD4-GP120 COMPLEX.
Csillag HIV-1 subtype C in Brazil.
WO2007123906A3 (en) Recombinant antigens for diagnosis and prevention of murine typhus
WO2005089231A3 (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PH PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001982248

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001982248

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001982248

Country of ref document: EP